Protocol Ledger

NCT04236141 · Phase III · TERMINATED

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Lar

Interventional Phase III clinical trial protocol NCT04236141 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-07-10 Enrollment: 42 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04236141
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04236141
Protocol FieldVerified Registry Value
NCT IdentifierNCT04236141
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment42 participants (ACTUAL)
Registered Start Date2020-07-10
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04236141
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
West China Hospital,Sichuan UniversityChengdu, ChinaOpen Hospital Dossier ->
Harbin Medical University Cancer HospitalHarbin, ChinaOpen Hospital Dossier ->
Jiangsu Cancer HospitalNanjing, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI